HK1214959A1 - 流感病毒重配 - Google Patents

流感病毒重配 Download PDF

Info

Publication number
HK1214959A1
HK1214959A1 HK16102968.6A HK16102968A HK1214959A1 HK 1214959 A1 HK1214959 A1 HK 1214959A1 HK 16102968 A HK16102968 A HK 16102968A HK 1214959 A1 HK1214959 A1 HK 1214959A1
Authority
HK
Hong Kong
Prior art keywords
viren
reassortant influenza
influenza
reassortant
viruses
Prior art date
Application number
HK16102968.6A
Other languages
English (en)
Chinese (zh)
Inventor
Mason Peter
Ralph Dormitzer Philip
Trusheim Heidi
Suphaphiphat Pirada
Original Assignee
Novartis Ag
Synthetic Genomics Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Synthetic Genomics Vaccines, Inc. filed Critical Novartis Ag
Publication of HK1214959A1 publication Critical patent/HK1214959A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • C12N2760/16152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HK16102968.6A 2012-12-03 2013-12-02 流感病毒重配 HK1214959A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732809P 2012-12-03 2012-12-03
US61/732,809 2012-12-03
PCT/EP2013/075294 WO2014086732A2 (en) 2012-12-03 2013-12-02 Influenza virus reassortment

Publications (1)

Publication Number Publication Date
HK1214959A1 true HK1214959A1 (zh) 2016-08-12

Family

ID=49713076

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102968.6A HK1214959A1 (zh) 2012-12-03 2013-12-02 流感病毒重配

Country Status (11)

Country Link
US (3) US9708585B2 (enExample)
EP (1) EP2925356A2 (enExample)
JP (1) JP6421128B2 (enExample)
KR (1) KR20150110494A (enExample)
CN (1) CN105120893B (enExample)
AU (2) AU2013354219A1 (enExample)
BR (1) BR112015012380A2 (enExample)
CA (1) CA2893429A1 (enExample)
HK (1) HK1214959A1 (enExample)
MX (1) MX2015006927A (enExample)
WO (1) WO2014086732A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013354219A1 (en) * 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
WO2016172588A1 (en) * 2015-04-24 2016-10-27 Andrew Cox Attenuated influenza vaccines and uses thereof
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
GB201602535D0 (en) * 2016-02-12 2016-03-30 Univ Edinburgh Improved flu vaccine yield
WO2019044636A1 (ja) * 2017-08-28 2019-03-07 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルスの段階的作出方法
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR101954904B1 (ko) 2018-10-15 2019-03-06 남종규 복층의 태양광 설치 구조
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP1098961B1 (en) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP2009532352A (ja) * 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン,エルエルシー イヌ細胞中でマイナス鎖ウイルスrnaを発現させるための方法および組成物
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008157419A2 (en) * 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
ES2675771T3 (es) * 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
EP2233152A1 (en) 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
EP2448598B1 (en) * 2009-06-25 2016-03-30 MedImmune, LLC Swine influenza hemagglutinin variants
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
JP5876036B2 (ja) * 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
AU2013354219A1 (en) * 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren

Also Published As

Publication number Publication date
JP6421128B2 (ja) 2018-11-07
AU2018232956B2 (en) 2020-10-01
US20150315548A1 (en) 2015-11-05
EP2925356A2 (en) 2015-10-07
US20200155666A1 (en) 2020-05-21
KR20150110494A (ko) 2015-10-02
CN105120893B (zh) 2018-11-13
BR112015012380A2 (pt) 2017-09-12
CN105120893A (zh) 2015-12-02
US20170326227A1 (en) 2017-11-16
US9708585B2 (en) 2017-07-18
AU2013354219A1 (en) 2015-07-02
WO2014086732A2 (en) 2014-06-12
WO2014086732A3 (en) 2014-07-24
JP2016501020A (ja) 2016-01-18
AU2018232956A1 (en) 2018-10-11
CA2893429A1 (en) 2014-06-12
US10500266B2 (en) 2019-12-10
WO2014086732A8 (en) 2018-12-06
MX2015006927A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
WO2013087945A3 (en) Influenza virus reassortment
WO2014141125A3 (en) Influenza b virus reassortment
WO2014086732A3 (en) Reassortant influenza a viren
HK1222882A1 (zh) 流感病毒重配
WO2014041560A3 (en) Process for the preparation of teneligliptin
BR112014026802A2 (pt) processo para a preparação de um a, \omega-cn diol.
BR112015003101A2 (pt) processo para a preparação de um composto.
EP3146203A4 (en) Vertical axis turbine clustering
HK1217638A1 (zh) 流感病毒重配
WO2014118606A3 (en) A novel process for the preparation of silodosin
EP2888230A4 (en) Improved process for the preparation of atazanavir bisulfate
EP3221320A4 (en) A process for the preparation of ibrutinib
WO2014016657A8 (en) Process for the preparation of phosphonium sulfonates
AU2012254976B2 (en) A lock assembly
AU2012900386A0 (en) Aerobot Ring
EP3241232A4 (en) Methods for the continuous, large-scale manufacture of functional nanostructures
AU2012903108A0 (en) A Structural Blank
AU2012900874A0 (en) Radial fit coupling bolts
AU2012903533A0 (en) Detecting the Nature of a Communication
AU2015901454A0 (en) Concentrated, vertical axis, fluid power turbine
AU2012903452A0 (en) Turbine assembly
AU2012903417A0 (en) Turbine Assembly
CA2814250A1 (en) A machine which can convert the force of gravity into a useable form, namely a turning shaft
TH1401003731A (th) กระบวนการสำหรับการผลิตของ 1,3-บิวทาไดอีน
AU2012903313A0 (en) Free stream, omni directional fluid power turbine